References
1. Kyle RA, Linos A, Beard CM, et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood. 1992;79(7):1817-1822.
2. Yakupova EI, Bobyleva LG, Vikhlyantsev IM, Bobylev AG. Congo Red and amyloids: history and relationship. Biosci Rep. 2019;39(1):BSR20181415. Published 2019 Jan 15. doi:10.1042/BSR20181415.
3. Palladini G, Milani P, Merlini G. Novel strategies for the diagnosis and treatment of cardiac amyloidosis. Expert Rev Cardiovasc Ther. 2015;13(11):1195-1211. doi:10.1586/14779072.2015.1093936.
4. Merlini G, Palladini G. Differential diagnosis of monoclonal gammopathy of undetermined significance. Hematology Am Soc Hematol Educ Program. 2012; 2012:595-603. doi:10.1182/asheducation-2012.1.595.
5. Palladini G, Milani P, Merlini G. Management of AL amyloidosis in 2020. Hematology Am Soc Hematol Educ Program. 2020;2020(1):363-371. doi:10.1182/hematology.2020006913.
6. Palladini G, Merlini G. What is new in diagnosis and management of light chain amyloidosis?. Blood. 2016;128(2):159-168. doi:10.1182/blood-2016-01-629790.
7. Bochtler T, Hegenbart U, Cremer FW, et al. Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability. Blood. 2008;111(9):4700-4705. doi:10.1182/blood-2007-11-12210.
8. Sperry BW, Vranian MN, Hachamovitch R, et al. Are classic predictors of voltage valid in cardiac amyloidosis? A contemporary analysis of electrocardiographic findings. Int J Cardiol. 2016;214:477-481. doi:10.1016/j.ijcard.2016.04.030.
9. Oda S, Kidoh M, Nagayama Y, et al. Trends in Diagnostic Imaging of Cardiac Amyloidosis: Emerging Knowledge and Concepts. Radiographics. 2020;40(4):961-981. doi:10.1148/rg.2020190069.
10. Quarta CC, Gonzalez-Lopez E, Gilbertson JA, et al. Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis. Eur Heart J. 2017;38(24):1905-1908. doi:10.1093/eurheartj/ehx047.
11. Saha A, Theis JD, Vrana JA, Dubey NK, Batra VV, Sethi S. AA amyloidosis associated with hepatitis B. Nephrol Dial Transplant. 2011;26(7):2407-2412. doi:10.1093/ndt/gfr224.
12. Denman J, Manavi K, Cook M. Lenalidomide as a treatment for relapsed AL amyloidosis in an HIV-positive patient. Int J STD AIDS. 2017;28(10):1045-1047. doi:10.1177/095646241769456.
13. Mansour M, Moustapha C, Maria F et al. Multiple Myeloma Secondary to HIV Infection, Revealed by Renal Failure: About a Case. Open J Nephrol. 2019;9:20-25. doi: 10.4236/ojneph.2019.91002.
14. Breillat P, Pourcher V, Deshayes S, et al. AA Amyloidosis in the Course of HIV Infection: A Report of 19 Cases Including 4 New French Cases and a Comprehensive Review of Literature. Nephron. 2021;145(6):675-683. doi:10.1159/000516982.
15 Amara S, Dezube BJ, Cooley TP, Pantanowitz L, Aboulafia DM. HIV-associated monoclonal gammopathy: a retrospective analysis of 25 patients. Clin Infect Dis. 2006;43(9):1198-1205. doi:10.1086/508351.